Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06692192 · ClinicalTrials.gov registry record · Phase 1
The RECAP2 Study: Midazolam and Psilocybin
A Phase 1 study of Psilocybin, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06692192 is a Phase 1 study of Psilocybin that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06692192, a Phase 1 study of Psilocybin, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing. Participants will: * Receive one of four possible combinations of medications * Undergo an MRI * Complete questionnaires * Undergo transcranial magnetic stimulation (TMS) and EEG
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG Psilocybin
- DRUG Saline
Study Locations (1)
Wisconsin
- UW School of Medicine and Public Health - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06692192
The ClinicalTrials.gov registry entry for NCT06692192 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psilocybin appearing as the primary indexed condition, and to 3 interventions - of which Midazolam is the first listed.
NCT06692192 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06692192 about?
NCT06692192 is a clinical study titled "The RECAP2 Study: Midazolam and Psilocybin". The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Researchers will compare different doses of psilocyb...
What is the current status of trial NCT06692192?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-08-07. Estimated completion is 2027-12.
What conditions does trial NCT06692192 study?
This clinical trial studies the following conditions: Psilocybin.
What interventions are being tested in trial NCT06692192?
The interventions under investigation include: Midazolam (DRUG), Psilocybin (DRUG), Saline (DRUG).
Who is sponsoring clinical trial NCT06692192?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06692192 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psilocybin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.